Low Concentrations Of Anti-C5aR Antibodies, But Not Anti-C3aR Antibodies, In Patients With EGPA Linked To Disease Activity And Relapse, Study Finds

Rare Disease Advisor (3/28, Jacobs) reported a study found that among patients with eosinophilic granulomatosis with polyangiitis (EGPA), “low concentrations of anti-C5aR antibodies, but not anti-C3aR antibodies, are reflective of disease activity and relapse. This, in turn, suggests that C5aR is an immune checkpoint that is regulated by endogenous anti-C5aR antibodies in patients with AAV.” Researchers concluded, “Further studies are needed to determine the role of endogenous antibodies on the C5a/C5aR-axis and complement activation in EGPA.” The study was published in RMD Open.